Months after Valeant Pharmaceuticals International Inc. said it would make discounts available to U.S. hospitals for two high-priced heart drugs, some medical centers say they have yet to see a cent of savings. Valeant became the face of high American drug prices when it acquired Isuprel and Nitropress last year and immediately raised their prices…